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APACHE = Acute Physiology and Chronic Health Evaluation; ARDS = acute respiratory distress syndrome; FiO2 = fractional inspired oxygen; 
GCS = Glasgow Come Scale; ICU = intensive care unit; PaO2 = arterial partial oxygen tension; SOFA = Sequential Organ Failure Assessment.
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This report is based on the transcript of a roundtable debate
held at the 23rd International Symposium on Intensive Care
and Emergency Medicine (ISICEM), Brussels, Belgium,
18–21 March 2003. The participants of the debate were
Jean-Louis Vincent (Brussels, Belgium), Julia Wendon
(London, UK), Johan Groeneveld (Amsterdam, The
Netherlands), John C Marshall (Toronto, Canada), Stephen
Streat (Auckland, New Zealand) and Jean Carlet (Paris,
France).
[Jean-Louis Vincent] Thank you very much indeed, and let’s
move to the fourth letter – ‘O’. The concepts have evolved
over time, and I would like to start by asking the panel
whether they agree that we need to stratify organ
dysfunction, perhaps with several other levels of organ
dysfunction, or if they prefer to stick to respiratory failure
versus no respiratory failure, renal failure versus no renal
failure, and that kind of dichotomous separation.
My next question of course will go to the various organs, and
we may ask, for example, whether we can improve the ways
to diagnose neurological status, with the Glasgow Coma
Score, and liver dysfunction, with bilirubin. Perhaps we also
need to ask whether we could better evaluate gut function or
metabolic function – should we speak about tolerance to
feeding, insulin requirements and that sort of thing?
But let’s start with the first general question – again, do
you agree that there is a need for stratification or would
you be happy with the more dichotomous separation? I
think this question is particularly relevant when it refers to
renal dysfunction because I’ve spoken recently to a
number of intensivists with a special interest in renal
function and they say that, as you have acute lung injury
and ARDS [acute respiratory distress syndrome] in
respiratory dysfunction, maybe we need to have a common
definition of renal failure. So do we agree with this
proposal?
[John C Marshall] Intuitively, I’ve always liked the idea of
describing organ dysfunction as an intervention – in other
words, ventilation or what you have to do to treat renal failure
– having a sense that things are basically OK or things have
completely failed or you’re somewhere in the middle. So to
me, the acute lung injury model is a nice reflection of that. So
I think there’s probably merits to having several levels. At this
stage I think our understanding is that the more refinement
we have in describing something, the more potential you
have to get out of it. Obviously, continuous variables give you
more information than dichotomous variables when you use
statistical analysis, and at this stage we’re still trying to
generate information – we don’t really know where the cut
point is.
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[Julia Wendon] I’m a very simple person. I think that organ
failure is, just by looking at a patient, variable – mild,
moderate, severe, however you want to define it. To my way
of thinking, a lot of the things that define those organ failures
go across them, so that something that might be important in
renal failure might also be important in the cardiovascular
system. I agree absolutely that we need to make them
broader than they are at the moment; they need to include
metabolism – we need to look at gut function in more detail
than we have in the past. We must also take account of
interventions, and the scoring system must take into account
whether we have intervened yet, how much we’ve intervened
and to what level.
[Johan Groeneveld] If I might continue along those lines and
come back to how I feel about treatment dependency or
independency and how to judge organ failure, the best way
to do it in my view is to be an observer, independent, to rule
out a bit of the treatment dependency of your assessments.
For example, one physician could spend half an hour longer
waiting for intubation and mechanical ventilation in a patient
with respiratory insufficiency than another. So, to improve
objectivity it may be wise to remove a bit from treatment
dependency, rather than incorporating it into the assessment
itself, except if you accept that it could be a different type of
assessment, independent from your organ assessment.
The second thing that comes up following your original
question – if you would favour a continuous level-wise versus
a dichotomous assessment – I would say that is a matter of
how you would prove objectively that the continuous level-
wise assessment is more predictive – linearly additive – that
one level is truly worse than the other level, in some
objectively proven model. If you can prove that it’s more
predictive then I would go for the level-wise assessment. So
it’s highly dependent on what you want to predict as to how
you would design it a priori for that purpose.
[Jean Carlet] I think we need some kind of global score giving
an idea of the intensity of the severity of the disease. It’s
exactly what the people who developed SAPS [Simplified
Acute Physiology Score] and APACHE [Acute Physiology
and Chronic Health Evaluation] really wanted – to try to find a
way to give a global indication of the severity. By the way, we
can still use those – it’s not necessarily organ system failures.
But in addition I think we need information about the different
kind of failures, because all are not comparable. I personally
have a big problem to be convinced that putting shock at the
same level as another one is appropriate – I am not sure, and
this really worries me a lot. I was taught many years ago that
shock is not only haemodynamic abnormalities but is far more
– it includes the effects on the organs. So now if we define
shock as just a fall in blood pressure, even if it’s sustained,
it’s a problem. So I think we still have a lot of efforts to put in
to describe those sorts of organ failures better, and I don’t
feel comfortable about the way we use it. It’s important
because as you know the indications of activated protein C
are now defined at a certain level of severity, and if you chose
to select an APACHE score or the number of organs failing
or the presence of shock, you will not necessarily pick up the
same patients.
[Stephen Streat] I agree with Johan that theoretically one
should seek a measurement system which is treatment
independent, but for the reason that I’ve alluded to before
about lead-time bias and the changing system it’s practically
impossible. And therefore I believe you’d need to have an
equally objective measure of the treatment intensity. I agree
with John’s suggestion that, at the beginning, when one’s
trying to define whether a dichotomous or continuous
process is likely to provide you with better information, you
should start by collecting continuous information and seeking
where the dichotomy should lie. My own personal bias is that
we need something more than a dichotomy but much less
than a continuous variable. Maybe we’re talking about a
3-point or, at most, a 4-point scale; we’re not talking about
something which is enormous. I do share your view that we
have focused on shock as if it were a cardiovascular problem
whereas in fact it’s a manifestation of a much more deep-
rooted problem.
[J-LV] The therapeutic aspect is very important because, if I
return to the reference to renal dysfunction, some people may
use haemofiltration very early on, perhaps with high-flux
filtration in the early stages of septic shock, whereas others
may wait until there is a very positive fluid balance with a high
urea or whatever before starting it. So just putting
haemofiltration into the system may result in very different
scores in one unit versus another. John, initially you were very
reluctant to introduce any therapeutic variables into your
score.
[JCM] My view has always been that these are two important
related sides of a problem that give us different types of
information in evaluating differing questions. So on the one
level we have the question – is there a biological process
going on here, is there a biological effect with an intervention,
how severe is that biological effect? It’s difficult for all sorts
of reasons to find biology based on what the clinician does
because we do different things with different biology. I agree
completely that it’s important to have a description of organ
dysfunction that is, to the maximal extent possible,
independent of therapeutic intervention. That was one of the
original precepts of the MODS [Multiple Organ Dysfunction
Score] score.
On the other hand I’m very much persuaded by the argument
that it really doesn’t matter what your PaO2/FiO2 [arterial
partial oxygen tension/fractional inspired oxygen] ratio is, or
what your creatinine is, or your urine output. If you’re a patient
what matters is, do you have a tube down your throat?, do
you have a catheter in your groin? – it is organ dysfunction as262
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a clinical outcome. I think in any area of medicine we say that
we’ve got a potential intervention – is there a biologic effect?
And if so, is there a clinical benefit based on that? I think we
need the next generation of organ dysfunction scores to
integrate variables looking at biologic effect with variables
looking at clinical consequences. That will not only tell us an
awful lot about whether a therapy that works actually helps
patients, but will give us wonderful insights into how we as a
community of practitioners differ in how we treat deranged
biology in patients, which actually gets back to the ‘P’ in the
PIRO model.
This is a very interesting discussion because it’s touching on
some of the wonderfully complex issues. The other one
related to this is, when is an organ dysfunction an outcome
and when is it the disease that we’re treating? In other
words, in cardiovascular dysfunction, is shock the disease or
is it the outcome of the disease that we’re trying to measure?
Is nosocomial infection actually a form of organ dysfunction
or is sepsis the disease process that we’re trying to treat? I
don’t know if it matters – but I think it’s important that we
address that question explicitly.
[Audience member] Don’t you consider that organ
dysfunction scores, APACHE scores, are about the same
level – aren’t we trying to define our populations a little
better? Don’t you think that APACHE scores do not tell you
whether the kidneys are failing?
[JCM] We want both. Initially you said it’s a way to describe
the intensity of care and severity of the patient, but it’s not
something that is meant to predict mortality. But in fact it
does. So we are always balancing between a system to
describe the picture, the intensity including the intensity of
what we are doing, and another score. Which is really the
most appropriate to describe severity, so that we can predict
mortality, at least in big groups? And we are always in-
between – we never decide exactly what we want to do. In
this case, we probably should decide. If you want to describe
severity I am very convinced by Jean-Roger Le Gall, Stan
Lemeshow, and Bill Knaus, that we should not put therapy in
it. I am really convinced.
If you heard John’s remark about physiological variables and
therapies used, does it mean we should have a 2-level scale,
with respiratory failure, PaO2/FiO2 ratio, and at level B, the
type of respiratory support, for renal the degree of increase in
creatinine … Johan, you don’t agree?
[JG] I like your idea, as always, but my feeling is that we
should be more specific, we should design a system and see
objectively whether that works in terms of predictive value;
design your organ failure system separately from your
treatment system. I’m not sure if there are data available on
that score, but it should be looked into, in some large
databases perhaps.
[J-LV] In the SOAP study, for instance, mechanical ventilation
was a very strong predictor of outcome.
[JG] Independently of the respiratory SOFA [Sequential
Organ Failure Assessment]?
[J-LV] Yes, independently of the respiratory SOFA. Now
there may be some ethical questions associated with it,
because perhaps there are not many patients dying in the
ICU [intensive care unit] without a tube in their throat.
[JW] Doesn’t that also raise the point – does the treatment
actually just make the figures that we measure better or does
it actually impact the organ dysfunction - and that’s perhaps
where even treatment needs to be separated somewhat. And
even if we can’t do it now, the aim of collating such data
would be to enable us to answer that question over time.
[SS] This is what concerns me the most – the possibility of
‘gaming’ the scores by the therapies that you do. Now does
that relate to outcome? Are you better predicted by the
gamed or the ungamed score, or does it not matter? It’s an
empirical question but we don’t have that information.
[J-LV] Maybe changes over time would be valuable. There
was a paper from our group (Lopes et al.) in JAMA last year
showing that the delta SOFA score is highly correlated with
outcome – and actually we’re using it now in our clinical
trials.
[Audience member] But this is not treatment, it changes
upon treatment – but what you’re referring to is some
additional treatment variables.
[J-LV] It’s still difficult to separate a change in function in time
from a change in therapy.
[JC] Since you mentioned this issue of trends, I think that the
trends in the first 12 hours are really the key. So we should
probably use those scores – SOFA and some other ones, it
doesn’t matter to me. There are some data showing that the
trends in the first few hours or days are far more important
than the absolute level at the beginning, and we should use it
more.
[Audience member] There may be a drawback here because
when you are approaching death it is far more easy to predict
it than in the beginning, so this is a two-edged sword. The
closer you get to death the more easy it is to predict. The
change in SOFA score over a limited time period may be
useful, of course it should be – more useful than the initial
one. This is not unexpected though.
[J-LV] We are studying it on the data from the PROWESS
study. It’s a little too early to show you the data, we’re still
working on it, but it’s amazing to see how we can predict263
outcome in the first 24 hours. It seems that beyond the
24 hours the prognosis is already largely established.
[Audience member] When we spoke about markers before,
some, if not all, of them are probably mediators, so I wonder
whether in the search for a better definition of organ failure
we should incorporate markers? For example, in the vascular
compartment the elevated markers probably have the role of
regulating the systemic part of the response of the host
response, but when we do the same measurements in, say, a
bronchoalveolar lavage we see different levels, and markers
in different compartments do not necessarily correlate. So I
wonder whether, with our definitions of ALI [acute lung
injury]/ARDS, we could do a better job in defining respiratory
failure by including parameters that we could measure?
[J-LV] There is a lot of biological variability there and I’m sure
that our panelists will say that we are very interested in
clinical parameters as well.
Julia – we are not quantifying liver dysfunction very well – we
just look at bilirubin, etc. – but what can enzymes tell us? In
many disease states enzymes can be elevated, so it’s fairly
nonspecific; are there any other simple tests we can do?
[JW] Simple tests are difficult, as you say. You can look at
conjugated bilirubin – it’s got to be conjugated, people don’t
even understand that. The transaminases go up in all sorts
of diseases – it’s hard to say it’s liver specific. The
hepatologists would say that we should look at albumin –
but we know that that’s pretty useless in critical care. If
you’re using a starch versus an albumin as your colloid or
crystalloid you’re going to get very different results, so I’ve
got concerns there. No one in reality at the bedside is going
to put hepatic vein catheters in to look at hepatic uptake or
splanchnic blood flow. I think perhaps what we’ve got to do
is to return to simpler things, maybe a lactate flux test. In the
old days we used to use lactate buffers in sick patients –
infusing lactate was a great way to assess hepatic lactate
metabolism – but we don’t do that any more. In addition,
maybe – and I think we must do more work on it – we could
think about using indocyanine green [ICG] by finger probe.
It’s a composite measure; it has its problems, but lactate
and base deficit are composite measures and it doesn’t stop
us using those. So I think over the next few years we will see
an expansion of liver assessment.
[J-LV] Any proposal for the evaluation of gut dysfunction? Of
course the ability to tolerate feeding may depend on the type
of patient, and perhaps your own protocols, but is there a
way? Not really.
My next question is, should we include insulin requirements?
[JCM] I think the notion of incorporating some measure of
endocrine function is intuitively a very appealing one. I’m not
an endocrinologist and I’m not sure what an endocrinologist
would say about the notion that the entire endocrine system
was one and we could equate insulin requirements to thyroid
function to sex hormones to releasing hormones to adrenal
status. Essentially, what one wants to do in describing organ
dysfunction is to come up with a construct that looks like the
dimensions of the patients that we treat in the ICU. So we
think about a lung failing, a heart failing, about neurologic
dysfunction, and that’s one important way in which it differs
from a generic severity measure like APACHE. Increasingly,
the endocrine system is one of those systems, so I don’t
really know what the outcome measure would be.
One of the curious things you find when you do that is any
one you look at is no longer significant when you look at it in
the context of all the others. We’ve seen that with ARDS, for
example, patients don’t die of ARDS, they die of multiple
organ dysfunction. But you can do that with any other organ
dysfunction and it simply reflects the fact that, although we
have to think about them in isolation, we are treating patients
who are entire species.
[SS] Can I take a slightly different viewpoint? Going back to
what you told us at the beginning about the independent
deleterious effects of positive fluid balance in the SOAP
study, I’m intrigued about the possibility of measuring
something that is related to the disposal of intravenous fluid
– the Trans Escape Rate of albumin, maybe, something to do
with interstitial fluid compliance, something to do with the
dynamic state of the solid-gel phase in the interstitial site –
whatever it is that drives this behavior which is independent
of vasodilatation and cardiac depression but is part of the
syndrome of fluid disposal.
[J-LV] This is interesting but it gets into quite sophisticated
analysis that Johan knows about well …
[JG] It increases in sepsis but I’m not sure whether this is a
bedside measurement with any predictive value. It has some
pathophysiological significance but I’m not sure whether it
could be incorporated into this system as an independent,
easily obtainable predictive measure. So I’m hesitating.
[JW] Staying along those lines, it’s not a direct measure of
capillary leak. But if you’ve got someone who’s leaking who’s
got a lot of fluid on board – perhaps also someone who also
isn’t tolerating their enteral feeding as well, even if you’ve got
a post-pyloric tube down there as well so you don’t know
what’s happening to that food in the small bowel – should we
start using intra-abdominal pressure more as a prognostic
indicator, and incorporate that into the definition of gut
failure?
[JCM] That’s a really interesting point; what about the delta
between the intra-abdominal pressure and central venous
pressure?
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[J-LV] What about neurological function? We’re still left with
the Glasgow Coma Score – we haven’t found anything
better – and of course it’s difficult in the patient treated with
sedative agents because we have to use an ‘assumed’ score.
Is there anything better that we can consider, any opinions
about how to evaluate neurological function in ICU patients?
[JG] Even if the Glasgow Coma Score [GCS] has some
drawbacks, I think it’s a fairly well-validated system in terms
of prognosis for a wide variety of neurological conditions. So
before getting rid of a system and designing a new one or an
additional one, we must be very secure about losing a
validated system that has been used for so many years
already.
[JCM] For all its weaknesses, we looked at the GCS in the
MONARCH anti-TNF study, and the strongest signal of
organ dysfunction was a change in the GCS. And that was in
a blinded study where the GCS was being measured at 157
different sites, with people coming up with their best
estimate. So it actually does work in practice, in a variety of
conditions.
[JC] I think we can use many different scores – my problem
is not to use a score rather than another one. I think we
should look at trends and incorporate this into our models as
soon as possible. The other thing I wanted to say is I’m not
comfortable with using hypoxaemia if the initial disease is
pneumonia, and I think this is a big issue. It will be a big issue
for the ALI [acute lung injury] studies. So I think we have to
say something on this. I am not comfortable with the level
that we selected – 200 or whatever.
[JCM] Can I just make a point? One of the things that was in
the original ACCP/SCCM [American College of Chest
Physicians/Society of Critical Care Medicine] consensus
paper from 1991–1992 was the notion that we need to think
about organ dysfunction as primary or secondary. I forget
whose idea it was, but it really got thrown by the wayside –
the idea that primary organ dysfunction, for example
pulmonary contusions or pneumonia, is different from a
secondary pulmonary dysfunction in ARDS. Maybe that’s an
idea that should be revisited.
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